We chose 2cell lines derived from malignancies associated with genetically activated FGFR1(KG1a, 8p11-positive acute myeloid leukemia [AML]) and FGFR3 (RT-4, urothelialcarcinoma) that are also indications in which INCB054828 is currently beinginvestigated in phase 2 clinical trials. Here, FGFR3 is linked to acute myeloid leukemia.